SUPPORT HOTLINE (888) 901-2226
Donate Now

BRIEF TITLE: Sacituzumab Govitecan Versus Treatment of Physician's Choice in Subjects With Metastatic or Locally Advanced Unresectable Urothelial Cancer (TROPiCS-04)

A Randomized Open-Label Phase III Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Subjects With Metastatic or Locally Advanced Unresectable Urothelial Cancer (TROPiCS-04)

  • Org Study ID: IMMU-132-13
  • Secondary ID:
  • NCT ID: NCT04527991
  • NCT Alias:
  • Sponsor: Immunomedics, Inc. - Industry
  • Source: Immunomedics, Inc.

Brief Summary

This is a Phase III, global, multicenter, open-label randomized controlled trial in patients with metastatic or locally advanced unresectable urothelial cancer who have progressed after prior therapy with platinum-based regimen and anti-programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) therapy. Approximately 482 subjects from 90 global sites will be enrolled

Detailed Description

This is a Phase III, global, multicenter, open-label randomized controlled trial in which
approximately 482 subjects with metastatic or locally advanced unresectable UC who have
progressed after prior therapy with platinum-based regimen and anti-programmed cell death
protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) therapy will be randomized to either
sacituzumab govitecan arm or Treatment of Physician's Choice (TPC) arm.

Subjects in TPC arm will have 1 of 3 standard of care (SOC) chemotherapeutic options
including paclitaxel, docetaxel, and vinflunine. Subjects randomized to the sacituzumab
govitecan arm will receive 10 mg/kg of sacituzumab govitecan intravenously on Day 1 and Day 8
of 21-day cycles. Those randomized to the TPC arm will have the choice of receiving
paclitaxel, docetaxel, and vinflunine administered intravenously at SOC doses of 175, 75 and
320 mg/m2 respectively, on Day 1 of 21-day cycles.

Overal Status Start Date Phase Study Type
Recruiting November 16, 2020 Phase 3 Interventional

Primary Outcomes:

Primary Outcome 1 - Measure: Overall Survival (OS)

Primary Outcome 1 - Time Frame: Until study completion, up to 3.5 years


  • Urothelial Carcinoma
  • Bladder Cancer
  • Metastatic Urothelial Carcinoma
  • Locally Advanced Urothelial Cancer
  • Transitional Cell Carcinoma


Inclusion Criteria:

1. Female or male subjects, ≥ 18 years of age, able to understand and give written
informed consent.

2. Subjects with histologically documented metastatic or locally advanced unresectable UC
defined as [Tumor (T) 4b, any node (N) or Any T, N 2-3].

Tumors of upper and lower urinary tract are permitted. Mixed histologic types are
allowed if urothelial is the predominant histology.

3. ECOG performance status score of 0 or 1.

4. Subjects with progression or recurrence following receipt of platinum-containing
regimen (cisplatin or carboplatin) and anti PD-1/PD-L1 therapy for metastatic or
locally advanced unresectable disease will be enrolled.

1. Subjects with recurrence or progression ≤ 12 months following completion of
platinum-containing chemotherapy and/or anti PD-1/PD-L1 therapy given in
neo-adjuvant/adjuvant setting may utilize that line of therapy to be eligible for
the study. The 12-month period is counted from completion of platinum therapy or
surgical intervention.

2. Subjects who received only concurrent chemoradiation for bladder preservation
without further systemic therapy are not eligible to enroll in the study. The
substitution of carboplatin for cisplatin does not constitute a new regimen
provided no new chemotherapeutic agents were added to the regimen and no
progression was noted prior to the change in platinum.

5. Subjects with previously treated brain metastases may participate in the study
provided they have stable CNS disease for at least 4 weeks prior to the first dose of
study drug and stabilization of all neurologic symptoms, have no evidence of new or
enlarging brain metastases, and are not using steroids > 20 mg of prednisone (or
equivalent) daily for brain metastases for at least 7 days prior to first dose of the
study drug.

6. Adequate hematologic counts without transfusion or growth factor support within 1 week
of study drug initiation [hemoglobin ≥ 9 g/dL, absolute neutrophil count (ANC) ≥
1,500/mm3, and Platelets ≥ 100,000/µL].

7. Adequate hepatic function (Bilirubin ≤ 1.5 x institution upper limit of normal (IULN),
aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 x IULN or ≤
5 x IULN if known liver metastases and serum albumin > 3 g/dL).

Docetaxel will only be option in TPC arm for subjects with a total bilirubin ≤ 1 x
IULN, and an AST and/or ALT ≤ 1.5 x IULN if alkaline phosphatase is also > 2.5 x IULN.

8. Creatinine clearance ≥ 30 mL/min as assessed by the Cockcroft-Gault equation or other
validated instruments (e.g. Modification of Diet in Renal Disease [MDRD] equation).

9. Female subjects of childbearing potential must have a negative urine or serum
pregnancy test within 72 hours prior to receiving the first dose of study drug. If the
urine test is positive or cannot be confirmed as negative, a serum pregnancy test will
be required.

10. Female subjects of childbearing potential must be willing to use 2 methods of birth
control or be surgically sterile or abstain from heterosexual activity for the course
of the study through 6 months after the last dose of study drug. Subjects of
childbearing potential are those who have not been surgically sterilized or have not
been free from menses for > 2 years.

11. Male subjects must agree to use an adequate method of contraception starting with the
first dose of study therapy through 3 months after the last dose of study therapy.

Exclusion Criteria:

1. Women who are pregnant or lactating.

2. Have had a prior anti-cancer mAb/ ADC within 4 weeks prior to C1D1 or have had prior
chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks
prior to C1D1. Subjects participating in observational studies are eligible.

3. Have received prior chemotherapy for UC with all available SOC therapies in the
control arm (i.e., both prior paclitaxel and docetaxel in regions where vinflunine is
not an approved therapy, or prior paclitaxel, docetaxel and vinflunine in regions
where vinflunine is an approved therapy).

4. Have not recovered (i.e., ≤ Grade 1) from AEs due to previously administered
chemotherapeutic agent.

- Note: Subjects with ≤ Grade 2 neuropathy or any grade of alopecia are an
exception to this criterion and will qualify for the study.

- Note: If subjects received major surgery, they must have recovered adequately
from the toxicity and/or complications from the intervention prior to starting
study therapy.

5. Have previously received topoisomerase 1 inhibitors.

6. Have an active second malignancy.

• Note: Subjects with a history of malignancy that have been completely treated and
with no evidence of active cancer for 3 years prior to enrollment, or subjects with
surgically cured tumors with low risk of recurrence are allowed to enroll in the study
after discussion with the medical monitor.

7. Have active cardiac disease, defined as:

1. Myocardial infarction or unstable angina pectoris within 6 months of C1D1.

2. History of serious ventricular arrhythmia (i.e., ventricular tachycardia or
ventricular fibrillation), high-grade atrioventricular block, or other cardiac
arrhythmias requiring anti-arrhythmic medications (except for atrial fibrillation
that is well controlled with antiarrhythmic medication); history of QT interval

3. New York Heart Association (NYHA) Class III or greater congestive heart failure
or left ventricular ejection fraction of < 40%.

8. Have active chronic inflammatory bowel disease (ulcerative colitis, Crohn's disease)
or gastrointestinal (GI) perforation within 6 months of enrollment.

9. Have an active serious infection requiring anti-infective therapy (Contact medical
monitor for clarification).

10. Have known history of Human Immunodeficiency Virus (HIV)-1/2 with uncontrolled viral
load and on medications that may interfere with SN-38 metabolism.

11. Have active Hepatitis B Virus (HBV) or Hepatitis C Virus (HCV). In subjects with a
history of HBV or HCV, subjects with a detectable viral load will be excluded.

12. Have other concurrent medical or psychiatric conditions that, in the investigator's
opinion, may be likely to confound study interpretation or prevent completion of study
procedures and follow-up examinations.

13. Have inability to tolerate or are allergic to any potential TPC agent or sacituzumab
govitecan or unable or unwilling to receive the doses specified in the protocol.

14. Have inability to complete all specified study procedures for any reason.
Show More

Gender: All

Minimum Age: 18 Years

Maximum Age: N/A

Healthy Volunteers: No

Official Information

Name: Cabilia C. Pichardo, MD

Role: Study Director

Affiliation: Immunomedics, Inc.

Overall Contact

Name: Dianne Nowicke, MS

Phone: 973-865-4704



Facility Status Contact
BRCR Medical Center
Plantation, Florida 33322
United States
Univ of TN Medical Center
Knoxville, Tennessee 37920
United States
BRCR Medical Center
San Juan, 00907-1509
Puerto Rico